白细胞介素6受体单克隆抗体与骨髓间充质干细胞可减少急性脊髓损伤神经元的凋亡

Combined use of interleukin-6 receptor monoclonal antibody and bone marrow mesenchymal stem cells reduces neuronal apoptosis after acute spine cord injury

 BACKGROUND: Studies have suggested that interleukin-6 is crucial for inducing cell apoptosis after acute spinal cord injury. OBJECTIVE: To observe the effect of interleukin-6 receptor monoclonal antibody combined with bone marrow mesenchymal stem cells to treat acute spinal cord injury in rats. METHODS: Thirty Sprague-Dawley rats were randomly divided into sham group, model group (spinal cord injury group), treatment group 1 (interleukin-6 receptor monoclonal antibody transplantation group), treatment group 2 (bone marrow mesenchymal stem cell transplantation group), treatment group 3 (bone marrow mesenchymal stem cell+interleukin-6 receptor monoclonal antibody group), with six rats in each group. In the sham group, the spinal cord was only exposed with no injury, and in the other four groups, rat models of acute spinal cord injury were made using modified Allen’s method. Local injection treatment was performed in all the groups at 28 days after modeling. Basso, Beattie and Bresnahan (BBB) scoring and improved Tarlov scoring were used at 1 day before treatment and 1, 3, 7, 14, 28 days after treatment to test the hindlimb function. At 28 days after treatment, TUNEL method was used to detect cell apoptosis in the spinal cord. RESULTS AND CONCLUSION: Compared with the sham group, BBB scores and improved Tarlov scores were decreased significantly in the other four groups (P < 0.05). At 7 days after treatment, the BBB scores and improved Tarlov scores in the treatment group 3 were significantly higher than those in the model group (P < 0.05). At 14 days after treatment, the BBB scores and improved Tarlov scores in the treatment groups 1 and 2 were significantly higher than those in the model group (P < 0.05); compared with the treatment group 2, the BBB score and improved Tarlov score were significantly increased in the treatment group 3 (P < 0.05). Compared with the sham group, the number of apoptotic cells was significantly increased in the other four groups (P < 0.05); compared with the model group, the number of apoptotic cells was significantly decreased in the three treatment groups (P < 0.05); compared with the treatment group 2, the number of apoptotic cells was significantly lower in the treatment group 3 (P < 0.05). These findings indicate that the combined use of interleukin-6 receptor monoclonal antibody and bone marrow mesenchymal stem cell transplantation is better than bone marrow mesenchymal stem cell transplantation alone in the treatment of spinal cord injury, and interleukin-6 receptor monoclonal antibody reduces cell apoptosis in spinal cord injury, which is of positive significance for preventing against acute spinal cord injury.